Doxorubicin-containing composition and application thereof

A composition and doxorubicin technology, applied in the field of doxorubicin-containing compositions, can solve problems such as reports on the combined use of formononetin and doxorubicin, etc., and achieve tumor-inhibiting activity, reducing dosage, reducing Cardiotoxic effects

CN113288906AInactive Publication Date: 2021-08-24BEIJING UNIV OF CHINESE MEDICINE
1 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2021-08-24
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of anticancer drug compounds, in particular to a doxorubicin-containing composition and application thereof. The doxorubicin-containing composition comprises the following components in parts by weight: 0.01-10 parts of doxorubicin and 1-100 parts of formononetin. The invention also provides an application of the composition in preparation of a pharmaceutical composition for treating tumors, wherein the tumors refer to breast cancer, liver cancer or glioma. The combination of the doxorubicin and the formononetin can reduce the cardiotoxicity of the doxorubicin, the combination of the doxorubicin and the formononetin has a synergistic effect on tumor treatment, and the dosage of the doxorubicin can be reduced.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of pharmaceutical compositions, in particular to a composition containing doxorubicin and its application. Background technique

[0002] Doxorubicin, also known as 14-hydroxydaunorubicin, 14-hydroxydaunomycin, adriamycin, doxorubicin-power, doxorubicin, etc., its CAS registration number is 23214 -92-8, the structural formula is shown in formula Ⅰ.

[0003] Doxorubicin is an anti-tumor antibiotic, which can inhibit the synthesis of RNA and DNA. It has the strongest inhibitory effect on RNA and has a wide anti-tumor spectrum. Cyclic tumor cells have a killing effect. Clinically, it is mainly applicable to acute leukemia, and is effective for both acute lymphoblastic leukemia and myeloid leukemia. It is generally used as a second-line drug, that is, it can be considered when the first-line drug is resistant. Malignant lymphoma, can be used as the first drug alternately. Breast cancer, sarcoma, lung cancer, bladder ca...

Examples

experiment example 1

[0054] Experimental Example 1: Detection of resistance to doxorubicin-induced cardiotoxicity

[0055] 1. Animals and groups

[0056] 1.1 Mice were purchased from Speiford (Beijing) Biotechnology Co., Ltd. (Beijing ICP No. 20001007-1), 0000006524.

[0057] After 3 days of adaptive feeding, the mice were randomly divided into saline group (Saline), doxorubicin group (Dox), doxorubicin+formononetin low-dose group (Dox+QSG7-L), doxorubicin group Doxorubicin + formononetin medium dose group (Dox+QSG7-M), doxorubicin + formononetin high dose group (Dox+QSG7-H), doxorubicin + enalapril positive drug group (Dox+Enap) Wait for 6 groups. Both basic and clinical studies have shown that enalapril can reduce doxorubicin-induced cardiotoxicity and improve cardiac function, so it is used as a positive control drug in mouse experiments.

[0058] 1.2 Miniature pigs were purchased from Nongnong (Beijing) Biotechnology Co., Ltd. (Jingchang Yishui Xu Zhun [2020] No. 13522), 0000016148.

[005...

experiment example 2

[0165] Experimental example 2: Detection of anti-tumor activity

[0166] 1. Test method: Different tumor cells, including liver cancer cells (HepG2 cells), breast cancer cells (MCF-7 cells), human glioblastoma cells (U87 cells), were used in 8*10 4 The cells were inoculated into 96-well plates (100 μl / well) at a density of / mL, and stimulated according to the following grouping after 24 hours of culture. After 24 hours, the cell proliferation activity was detected by the CCK8 method with a microplate reader.

[0167] 2. Test groups:

[0168] Group 1: normal group (Control), QSG7 20μmol / L, QSG7 40μmol / L, QSG7 80μmol / L;

[0169] Group 2: normal group (Control), Dox 1 μmol / L, QSG7 80 μmol / L, Dox 1 μmol / L+QSG7 80 μmol / L, Dox 1 μmol / L+Dexra 10 μmol / L.

[0170] 3. Detection index: The OD value detected by the microplate reader represents the cell proliferation activity.

[0171] 4. Statistical method: Graphpad Prism 6.0 was used for data processing, expressed as Means±SD, Student...